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Abstract
Background: Fabry disease is an inherited metabolic disorder characterized by progressive lysosomal accumulation of
lipids in a variety of cell types, including neural cells. Small, unmyelinated nerve fibers are particularly affected and small
fiber peripheral neuropathy often clinically manifests at young age. Peripheral pain can be chronic and/or occur as
provoked attacks of excruciating pain. Manifestations of dysfunction of small autonomic fibers may include, among
others, impaired sweating, gastrointestinal dysmotility, and abnormal pain perception. Patients with Fabry disease often
remain undiagnosed until severe complications involving the kidney, heart, peripheral nerves and/or brain have arisen.
Methods: An international expert panel convened with the goal to provide guidance to clinicians who may
encounter unrecognized patients with Fabry disease on how to diagnose these patients early using simple
diagnostic tests. A further aim was to offer recommendations to control neuropathic pain.
Results: We describe the neuropathy in Fabry disease, focusing on peripheral small fiber dysfunction - the hallmark
of early neurologic involvement in this disorder. The clinical course of peripheral pain is summarized, and the
importance of medical history-taking, including family history, is highlighted. A thorough physical examination (e.g.,
angiokeratoma, corneal opacities) and simple non-invasive sensory perception tests could provide clues to the
diagnosis of Fabry disease. Reported early clinical benefits of enzyme replacement therapy include reduction of
neuropathic pain, and adequate management of residual pain to a tolerable and functional level can substantially
improve the quality of life for patients.
Conclusions: Our recommendations can assist in diagnosing Fabry small fiber neuropathy early, and offer clinicians
guidance in controlling peripheral pain. This is particularly important since management of pain in young patients
with Fabry disease appears to be inadequate.
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Fabry disease is a life-limiting genetic lysosomal storage
disorder with distressing early clinical symptoms related
to small fiber neuropathy [1-3]. The deficiency of lyso-
somal a-galactosidase A activity results in the progres-
sive accumulation of glycolipids in a variety of cell types
[4]. A cascade of overlapping pathologic events usually
leads to multisystemic disease. First symptoms (see
Table 1) typically arise in childhood or adolescence and
include, among others, peripheral pain, angiokeratoma
(Figure 1), and cornea verticillata (Figure 2) [1-3]. Ser-
ious complications developing in adulthood include pro-
gressive renal insufficiency, cardiac complications
(arrhythmia, hypertrophic cardiomyopathy), and/or cere-
brovascular complications (e.g. early stroke), and have
been reviewed elsewhere [5-9]. Although Fabry disease
is transmitted in an X-linked fashion, females commonly
manifest symptoms, presumably as a result of skewed X-
chromosome inactivation [10,11]. Their phenotypic pre-
sentations, however, are far more variable as compared
to males [7,10].
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small fibers of the peripheral and autonomic nervous
systems. Peripheral neuropathic pain in young patients
with Fabry disease can manifest as chronic, burning
pain and superimposed attacks of acute excruciating
pain (described in more detail later), dysesthesias, ther-
mal sensation deficits (primarily cold perception), and
paresthesias (e.g., painless tingling) [12-14]. Symptoms
related to autonomic nervous system dysfunction may
include hypohidrosis, impaired pupillary constriction
and saliva and tear production, gastrointestinal dysmoti-
lity (abdominal cramping pain, bloating, diarrhea, nau-
sea), and sensory losses.
The primary neuropathic insult in Fabry disease is
presumably due to a combination of factors that are
linked with accumulation of GL-3, and possibly with
deposition of its deacylated form [15]. Accumulated
GL-3, migrated from the plasma into neural cells or
synthesized in situ, can interfere with the function of
critical proteins, e.g., ion channels, thereby causing
nerve injury and dysfunction [12]. GL-3 inclusions
have been demonstrated in dermal vascular endothelial
and smooth muscle cells, endothelial and perithelial
cells of epineural and endoneural small blood vessels,
perineural cells, myelinated and unmyelinated axons,
and less often in Schwann cells [16-25]. The dorsal
root ganglia have fenestrated blood vessels and appear
particularly vulnerable for GL-3 accumulation (Figure
3) [26,27]. Also in the central nervous system, GL-3
appears to accumulate in regions where the blood-
brain barrier is more permeable (e.g., supraoptic, para-
ventricular and preoptic hypothalamus nuclei, dorsal
nucleus of the vagus) [26].
Luminal encroachment and occlusion of the vasa ner-
vorum of the peripheral nerves due to endothelial GL-3
storage, disturbed balance between vasodilatative and
vasoconstrictive mechanisms, and thrombotic complica-
tions are factors that may contribute to ischemic neural
damage [28,29]. Also, GL-3 accumulation in skin cells
may interfere with the function of intradermal sensory
receptors.
Although still insufficiently understood, peripheral
nerve injury may induce a variety of peripheral and cen-
tral mechanisms, e.g., axonal sensory hyperexcitability,
ectopic spontaneous firing, and central sensitization that
have been described elsewhere [12,13,30,31]. The extent
of overlap of these mechanisms in the various stages of
Fabry disease is uncertain.
Table 1 Possible early symptoms of Fabry disease
Organ
system
Sign/Symptom
General Reduced quality of life; reduced well-being; reduced
school/work performance and engagement in leisure
activities, including sports
Psychosocial and behavioral deficits
Poor weight gain
Nervous
system
Chronic burning pain
Attacks of excruciating pain
Paresthesias/dysesthesias
Sensory losses
Hypohidrosis/anhidrosis
Abdominal cramp, (post-prandial) diarrhoea, bloating,
nausea
Tinnitus, hearing loss
Dizziness
Skin Vascular lesions (angiokeratoma, Figure 1)
Eyes Corneal/lenticular opacities (seen on slit lamp
examination, Figure 2)
Vascular tortuosity (retina, conjunctiva)
Kidneys Microalbuminuria, proteinuria
Impaired concentration ability
Increased urinary GL-3 excretion
Renal hyperfiltration (early), decrease in glomerular
filtration rate
Heart ECG abnormalities (for example, short PR interval)
Arrhythmias, hypertrophic cardiomyopathy (young
adults)
Figure 1 Red-purple, non-blanching vascular skin lesions. Angiokeratoma are usually distributed on the buttocks, groin, umbilicus (left
figure) and upper thighs (bathing trunk distribution), and occasionally on lips and oral mucosa (right figure).
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Page 2 of 11An International Expert Panel on Neuropathy in
Fabry Disease convened on January 12
th,2 0 0 9 ,i n
Rome, Italy. The Panel was composed of 8 experts (7
physicians/physician scientists, 1 scientist) in the area
of Fabry disease and/or peripheral neuropathy from
the US, Canada, South America, and Europe. The aim
of the meeting (sponsored by Genzyme Corp.) was to
develop guidance on the clinical evaluation of early
stages of small fiber neuropathy in Fabry disease,
focusing on simple diagnostic tools that can be quickly
applied by the practitioner, and on treatment of the
neuropathic pain. The recommendations are supported
by a review of relevant medical literature published up
to September 2010. Given the well manageable number
of relevant publications, no specific criteria for litera-
ture review were used. Our recommendations can
assist in diagnosing Fabry small fiber neuropathy early,
and offer clinicians guidance in controlling peripheral
pain. This is particularly important since management
of pain in young patients with Fabry disease appears to
be inadequate [1].
Clinical course of neuropathic pain in Fabry disease
Burning, nagging pain with a symmetric distribution
pattern in the palms of the hands and soles of the feet
of children or adolescents and peripheral dysesthesias
are the first symptoms to raise alarm. Recurrent attacks
of pain ("pain crises”), described as “excruciating”, “ago-
nizing”, “lightning” or “stabbing” pain, often begin in the
distal parts of the extremities and may radiate proxi-
mally [12,32]. They can be so intense that the patient is
confined to bed [12], and episodes can occur daily [4].
They may be triggered by a rapidly changing core body
temperature (e.g., fever, stress, physical activity) presum-
ably due to a decreased ability to sweat [12,32], although
they have been noted even in patients with hyperhidro-
sis [33]. Additional triggering factors include sudden
exposure to cold, rapid changes in humidity, and fatigue
[ 3 4 ] .D e e pa c h e ,s i g n i f i c a n tj o i n tp a i n ,b o u t so fu n e x -
plained fever, and elevated erythrocyte sedimentation
rate can accompany a pain crisis [12,35,36].
Neuropathic pain was reported by ~60 and 80% of the
affected boys enrolled in the two Fabry disease registries,
usually beginning in childhood, and by ~40 to 60% of
a f f e c t e dg i r l s ,o f t e naf e wy e a r sl a t e rt h a ni nb o y s[ 1 , 2 ] .
Most adult males and 60 to 90% of females experience
some form of Fabry pain [13,37-39]. Over time, neuro-
pathic pain appears to diminish, perhaps due to progres-
sive loss of nerve fibers, but can also become more
severe [40,41].
It has recently been proposed to abandon the use of
“acroparesthesia” in the description of Fabry neuropathic
pain because, by definition, paresthesias are painless tin-
gling sensations [42]. In fact, paraesthesias appear to be
rather uncommon in Fabry disease as they were
reported by only ~10% of affected adults [42].
In children with Fabry small fiber neuropathy, reduc-
tions in feelings of well-being and in school attendance
and a reluctance to participate in sports, gymnastics,
and leisure activities are of particular concern. As the
patient ages, the symptoms lead to increasing neurologi-
cal disability and impairment of quality of life in both
males and females [7,10,43-45].
As in other conditions with chronic neuropathic pain,
pain medication dependence (e.g., opioids) and sub-
stance abuse can occur [46]. Patients may develop
social-adaptive or psychological functioning deficits
[47,48] and many become depressed, with the presence
of neuropathic pain being the strongest predictor of
depression [49]. Suicidal ideation has been reported in
patients with Fabry disease [49-51].
Small fiber dysfunction in Fabry disease
The pattern of small fiber dysfunction in Fabry disease
is seen in various other diseases characterized by periph-
eral neuropathy, including diabetes mellitus [52,53].
Figure 3 Dorsal root ganglion cells from a Fabry patient.T h e
ganglion cells are swollen by accumulation of glycolipids and
stained with Alcian blue (photo courtesy of E. Kaye).
Figure 2 Cornea verticillata. A bilateral, whorl-like corneal pattern
of cream colored lines in a patient with Fabry disease.
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t h ed i a g n o s i so fF a b r yd i s e a s es h o u l db eh i g h l ys u s -
pected. The neuropathy in Fabry disease is a length-
dependent neuropathy [12,54] typically associated with a
marked reduction of thinly myelinated Aδ fibers (med-
iating sharp pain, cold perception), unmyelinated C
fibers (pain, warmth perception), and loss of unmyeli-
nated autonomic fibers [17,19,21,23,24,40,55-59]. Female
patients, even when asymptomatic, may also be affected
by loss of small fiber function [39,54,60].
The thermal sensation deficits are initially more pro-
nounced in the feet than in hands, and gradually pro-
gress to more proximal parts (Figure 4) [12,39,59,61]. In
early stages, impairment of thermal stimuli primarily
involves cold perception (Aδ fibers), rather than warmth
perception (C fibers) [62], suggesting that the thinly
myelinated Aδ fibers are more vulnerable to GL-3-
induced damage [36,40,63,64].
Disappearance of pain may not necessarily reflect nerve
recovery but rather degeneration of nerve fibers and the
sensory neuropathy may progress to numbness and
hypoalgesia. Recently, an association between the severity
of small fiber neuropathy, determined by cold perception
in the feet, and progressive sensorineural hearing loss has
been reported, both in male and female patients [65].
Autonomic small fiber damage in Fabry disease is
l i k e l yt ob er e l a t e dt ot h ep a t i e n t s ’ gastrointestinal dys-
motility (e.g., abdominal cramps, bloating, diarrhea, nau-
sea), hypohidrosis, impaired pupillary constriction,
decreased tear and saliva formation, Raynaud phenom-
ena, sensory losses, reduced heart rate acceleration upon
exercise and, in advanced stages, orthostatic hypotension
[17,37,66]. The cutaneous response to scratch can be
diminished [17,67], and baroreflex-mediated vasocon-
striction can be deficient due to sympathetic vasomotor
nerve fiber dysfunction [68].
Figure 4 Photomicrographs of frozen skin sections (50 μm) from a Fabry patient. Samples immunoreacted with PGP 9.5 and were
processed for fluorescence microscopy with Cy3 labelled secondary antibodies. Note the lack of intraepidermal nerve fibers and persistence of
fibers pertaining to the subepidermal nerve plexus (arrows) in the sample from the lower leg skin of a Fabry patient (upper figure). Note the
dense innervation of the epidermis (arrows) in the sample from the back of the Fabry patient, taken at the dermatome Th 12 (lower figure). Bar
=5 0μm.
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post-prandial diarrhea after consumption of a high-fat
meal [69]. Both autonomic sudomotor nerve fibers and
sweat gland function are impaired in untreated patients
[37,70]. Hyperhidrosis can also be recognized in patients
with Fabry disease, mainly in females. If present, it often
manifests in childhood or adolescence [33].
Of note, the generally accepted assumption that auto-
nomic neuropathy plays an important role in the patho-
physiology of Fabry disease has recently been questioned
by one group of investigators [71]. The observation of
nearly normal male sexual function and autonomic con-
trol of the cardiovascular system in patients with Fabry
disease led the investigators to suggest that end-organ
damage, rather than autonomic dysfunction, might play
a prominent role in Fabry disease.
Large fiber dysfunction in Fabry disease
As large Aa and Ab fiber modalities (e.g., motor func-
tion, position, and vibration sensation) are generally
spared in early stages of Fabry disease, it is not surpris-
ing that the results of motor and sensory nerve conduc-
tion tests have mostly been normal [19,21,34,36,
40,57,61,66,72,73]. With progression of the disease, how-
ever, large fiber involvement with associated nerve con-
duction abnormalities may develop. Reductions of
compound muscle action potential amplitudes are seen
more often than the slowed conduction velocities [40].
Impaired vibration perception may be a consequence of
disturbed transmission of the synchronized impulse vol-
leys in large myelinated afferent Ab fibers, or by GL-3-
induced dysfunction of intradermal corpuscles (mainly
Pacinian corpuscles and Meissner bodies [74,75]) med-
iating the vibratory stimuli [40,73]. With age, more
severe abnormalities involving large fibers are expected
to occur as demonstrated by a significant influence of
age on vibratory perception [40].
The mechanisms contributing to development of large
nerve fiber abnormalities in a subset of patients are as
yet unclear. It has been suggested that Schwann cell
pathology due to GL-3 accumulation might account for
slowing of conduction velocities [40]. Uremia due to
Fabry end-stage renal disease and overuse of alcohol
may add to the large fiber pathology [40,55,66,76].
Median nerve conduction abnormalities may indicate
median nerve entrapment caused by GL-3 accumulation
in carpal tunnel structures. A prevalence of carpal tun-
nel syndrome of ~25% has been reported for both male
and female patients with Fabry disease [36,55].
Diagnosis and simple assessments
The early neurologic manifestations of Fabry disease are
initially often subtle and affected children are frequently
misdiagnosed as having rheumatism, viral infection,
growing pains, “bone problems”, psychogenic pain, cryp-
togenic pain, food intoxication, or non-specific gastroin-
testinal pain [77]. Although first symptoms appear in
childhood, correct diagnosis may be delayed until well
into adulthood. Data from the Fabry Registry shows that
the mean diagnostic delay was approximately 11 years
for both genders [10]. While still undiagnosed and
untreated, the disease increasingly impairs the young
patient’s well-being.
Children and young adults with unexplained periph-
eral neuropathic pains may be referred to the pediatri-
cian, or the pediatric/general rheumatologist or
neurologist. Therefore, they play a critical role in recog-
nizing the array of distinct early features of Fabry dis-
ease (Table 1), of which several are related to the small
fiber neuropathy. The importance of their role is under-
pinned by a recent Fabry screening study among indivi-
duals with small fiber neuropathy of unknown aetiology;
several previously unrecognized patients were diagnosed
with Fabry disease [53]. The differential diagnosis of
peripheral neuropathy can be significantly narrowed by
taking a detailed medical history (Table 2). This should
include information on the onset, quality, intensity and
distribution of pain symptoms, abnormal responses to
normally non-painful stimuli, triggering and exacerbat-
ing factors, psychological factors, changes of symptoms
over time, and coping skills. Previous and current use of
pain medications (prescription, non-prescription and
recreational drugs) and smoking habits should be docu-
mented. The patient’s general status, energy level, co-
morbidities, school, work and sport performance, and
lifestyle should be explored. Gastrointestinal problems
(abdominal pain, post-prandial diarrhea, number of
bowel movements per day, bloating, nausea) and hearing
problems need to be documented, as well as the family
history (e.g., renal/cardiac failure, transient ischemic
attack (TIA) or stroke, early death).
A neuropathy pain assessment scale should be used at
the initial assessment and follow up examinations. The
Neuropathy Symptoms and Change Questionnaire eval-
uates the number, severity and change of symptoms, as
well as motor, autonomic, large fiber and small fiber
sensory nerve function [78]. Other available neuropathic
pain evaluation tools include the Leeds Assessment of
Neuropathic Symptoms and Signs, Neuropathic Pain
Questionnaire, Neuropathic Pain Symptom Inventory,
Douleur Neuropathique en 4 questions, pain DETECT,
and ID-pain [79]. The Total Symptoms Score has been
used for grading of neuropathic pain in clinical studies
in diabetes and Fabry disease patients with peripheral
neuropathy [73,80].
The patients can also be asked to keep a (weekly) pain
diary. A more general pain assessment can be performed
by using, for example, the Pediatric Pain Questionnaire
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the Short-form McGill Pain Assessment Questionnaire
[81], is particularly easy to administer. Quality of life
can be assessed by using the Short Form-36 (SF-36
®)
Health Survey (http://www.sf-36.org) or Pediatric Qual-
ity of Life Inventory (PedsQL™) [82].
A complete physical examination should be performed
as it may provide clues to the diagnosis of Fabry disease
(Table 2). It should include measurement of height and
weight, heart rate (irregular pulse) and supine and
standing blood pressure to determine orthostatic hypo-
tension (defined as a drop in systolic blood pressure by
at least 20 mmHg, or in diastolic blood pressure by at
least 10 mmHg, within the first three minutes upon
active standing up from the sitting or supine position,
or upon passive head-up tilt) [83]. The skin should be
inspected for presence of vascular skin lesions (angio-
keratoma, Figure 1), particularly in the bathing trunk
area. Cornea verticillata (Figure 2) is readily detectable
by slit lamp examination and present in almost all males
and 70% of females with Fabry disease [32,84]. Routine
blood work-up is usually normal. Albuminuria may be
detected in young patients and is an antecedent to pro-
gressive Fabry nephropathy [85].
The neurologic examination in children, adolescents
and young adults should focus on sensations mediated
by peripheral small fibers, as overt central nervous sys-
tem involvement is usually not yet present (Table 2).
Relevant, easy to perform and non-invasive sensory
perception tests include cold, heat, light touch, pinprick,
pressure and vibration perception testing. Assessment of
allodynia and hyperalgesia should preferably be carried
out in the area of maximal pain. All tests should be per-
formed under comfortable ambient conditions and tem-
perature at the distal lower limbs.
Early in the course of small fiber neuropathy, impaired
appreciation of thermal stimuli primarily involves cold
perception rather than warm perception [39,62]. A
rather crude test of thermal perception consists of pla-
cing tubes filled with cold and warm water, a cold and
warm tuning fork, the handle of a reflex hammer, or
thermal discs with a polyvinyl surface on one side and a
metal surface on the other side (similar to the “Minne-
sota Thermal Discs” [86]) on the patient’sf o o t .C o l d
sensation can also be assessed by using acetone spray,
or by immersing one leg up to the mid thigh (or one
forearm) for 30 seconds into ice-cold water [34]. Normal
subjects report little discomfort to a brief immersion of
a limb in ice water, but the Fabry patient experiences
intense burning pain within 10-30 seconds.
Pain perception and hyperalgesia can be tested by
applying just enough pressure with a sharp pin to indent
the skin. Loss of discrimination between pinprick sensa-
tion and application of a blunt pressure sensation points
towards small fiber neuropathy.
Perception of light touch and mechanical allodynia
can be tested by lightly rubbing the skin with a cotton
swab or by lightly squeezing the patient’sl e g .V i b r a t i o n
Table 2 Medical history and examinations in young patients with Fabry disease
General status Decreased stamina and exercise; psychologic co-morbidities; school, work and sport participation and performance; smoking
SF-36
® Health Survey or PedsQL™
Pain Onset; quality; intensity; distribution; abnormal responses to stimuli; exacerbating factors; pain meds (past, current), McGill Pain
Questionnaire, Brief Pain Questionnaire, Pediatric Pain Questionnaire
Gastrointestinal Abdominal cramps; (post-prandial) diarrhea; number of bowel movements/day; bloating; nausea
Family history Renal/cardiac failure; TIA or stroke; early death
Complete physical examination
Including height; weight; pulse irregularity; supine and standing blood pressure; vascular skin lesions (Figure 1); cornea
clouding (requires slit lamp exam, Figure 2)
Neurologic examination
Thermal perception (cold/warm water tubes, a cold and warm tuning fork or reflex hammer, or thermal discs at dorsal foot, e.
g., “Minnesota Thermal Disks” [81])
Pain perception (pinprick to skin of limbs and trunk)
Light touch perception (cotton swab or lightly touching skin, e.g., on legs vs. feet, testing distal vs. proximal sensation)
Vibration perception (vibrating tuning fork (Rydell-Seiffer
®) to 1st metatarsal bone)
Sensorineural hearing loss (Rinne test, three-tone audiometry)
Definitive diagnosis
a-Galactosidase A enzyme activity in leukocytes or whole blood in males
GLA mutation analysis in females (known family mutation testing or full gene sequencing)
Genetic risk
assessment
Diagnosis should be followed by genetic testing of the entire family
Severity scoring
Neuropathy Staging Scheme [91], Neuropathy Symptoms and Change Questionnaire [78]
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Hz tuning fork to the first metatarsal bone [87].
Symmetrical sensorineural hearing loss can be
explored by performing the Rinne test. The stem of a
vibrating tuning fork (512 or 256 Hz) is placed on the
mastoid process until sound becomes inaudible; the fork
is then immediately placed outside the ear. In case of
sensorineural hearing loss, bone conduction and air con-
duction are both equally reduced. However, to reliably
assess or rule out hearing loss, three-tone audiometric
testing needs to be performed [88].
Abnormal results of the tests described above may lead
to more comprehensive examinations trying to document
the sensory abnormalities qualitatively and quantitatively.
A standardized quantitative sensory testing (QST) proto-
col to assess the somatosensory profile within 30 minutes
and diagnose a small fiber neuropathy is available
[53,56,89]. The QST battery consists of 7 tests measuring
thermal detection, thermal pain and mechanical detec-
tion thresholds and mechanical pain sensitivity. An
abbreviated version of this protocol assessing cold and
warm detection thresholds can be applied within
approximately 10 minutes and may facilitate the develop-
ment of new screening strategies for Fabry disease. Meth-
ods to test nerve conduction velocities, sympathetic skin
response, quantitative sudomotor axon reflex sweating,
saliva and tear formation, and other autonomic dysfunc-
tion are not further discussed in this manuscript that
focuses on simple bedside tests. Given the availability of
an accurate diagnostic laboratory test, nerve or skin biop-
sies are not required for diagnosing Fabry disease,
although skin biopsy can detect small fiber disease in yet
asymptomatic patients and may be used to quantify loss
of skin innervation [39].
Measuring a-galactosidase A enzyme activity in leuko-
cytes is the gold standard assay of diagnosis of Fabry
disease in males [4]. Many females with Fabry disease,
however, may have enzyme activity levels within the
normal range. Diagnosis in females, therefore, requires
genetic studies to detect or confirm the Fabry mutation.
Extended familial assessment identified, on average, five
family members with Fabry disease for every proband
[90]. Therefore, the importance of taking a family his-
tory and genetic testing in all members of the family of
a newly identified patient cannot be underestimated.
Evaluation and monitoring of the small fiber neuropa-
thy are important as the elicited signs and symptoms
may provide insight into possible pathophysiological
mechanisms and, in turn, may provide guidance on opti-
mal pain management. Given the progressive nature of
Fabry disease, regular objective and comparable moni-
toring of the neuropathy and its progression using
reproducible measures of staging is required for therapy
adjustment. Particularly useful may be the neuropathy
staging scheme developed by Dyck [91] as it scores sen-
sory, autonomic, and motor components separately, and
provides an overall stage. Other available methods to
s c o r es e v e r i t yi n c l u d et h eT o t a lS y m p t o mS c o r ef o r
grading of pain [73,80], and the Neuropathy Impairment
Score [92].
Treatment
Current management of pain in pediatric patients with
Fabry disease appears to be inadequate. This is as illu-
strated by the fact that the majority of children in the
Fabry Registry who had neuropathic pain reported not
to have received any pain medication [1].
Given the episodic and provoked nature of many of
the painful crises, it should be emphasized that identifi-
cation of individual provocateurs is important for con-
servative management. Patients can change their lifestyle
and take preventive measures to avoid exposure to, for
example, rapid changes in temperature. The goal of
pharmacological management of neuropathic pain
should be to decrease pain to a tolerable and functional
l e v e la n d ,t h e r e b y ,t oi m p r o v et h ep a t i e n t ’s quality of
life, activities of daily life, and psycho-social function.
We are not aware of any randomized controlled trial
of an analgesic for the treatment of painful peripheral
neuropathy in Fabry diseas e ;o n l ys o m ee m p i r i cu s eo f
drugs has been reported [93-95]. However, a substantial
body of evidence exists for the treatment of other types
of painful neuropathy and this may serve as a guide for
the physician treating the Fabry disease patient [96-99].
Pain treatment should generally consider the most likely
mechanism in each case. However, in the attempt to
achieve optimal pain management, multiple medications
targeting different aspects of the complex pathways
might be considered in patients with advanced disease.
It is recommendable to start pain medication(s) at low
dose, and to evaluate the tolerability and effectiveness of
a change in medication(s) after 2-3 weeks.
Anticonvulsants are commonly used to reduce pain in
neuropathic pain disorders, including diabetic neuro-
pathic pain [96-99]. Carbamazepine alone [95], or in
combination with pregabalin (rather than gabapentin)
[99], is recommended as first-line treatment in Fabry
neuropathic pain. Symptoms suggestive of autonomic
dysfunction should be monitored as dose-dependent
exacerbation of autonomic dysfunction has been
reported [95]. Antidepressants, particularly dual reup-
take inhibitors of both serotonin and norepinephrine
( S N R I s ;v e n l a f a x i n e ,d u l o x etine; black-box warning for
use in pediatric age group) are also viable options.
Because of their anti-cholinergic effect, tricyclic anti-
depressants have potential concomitant and difficult
side-effects in Fabry patients (e.g. accentuation of auto-
nomic instability). Prescription of opioids carries the
Burlina et al. BMC Neurology 2011, 11:61
http://www.biomedcentral.com/1471-2377/11/61
Page 7 of 11risk of drug dependence or abuse. Although they should
only be given if other therapeutic options are ineffective,
opioids may be helpful in the acute management of
intolerable pain crises [96-99]. Topical application of
anesthetics may provide relief of burning pain or
hyperalgesia.
With increasing disability and unpredictability and dif-
ficulty of controlling the pain, patients are at risk of
chronic depression [49]. Patients should be evaluated for
psychosocial and behavioral deficits and appropriately
treated.
Common non-neurologic symptoms of Fabry disease
and risk factors should be carefully monitored and trea-
ted as outlined in the general guidelines for the manage-
ment of Fabry disease patients [100]. Co-morbidities
must be addressed and smoking discouraged as it may
aggravate airflow obstruction commonly found in
patients with Fabry disease [101], and further increase
the risk of cardiovascular and cerebrovascular events.
Anti-platelet drugs (aspirin, clopidogrel) are recom-
mended for patients at risk of thrombotic events. Dysli-
pidemia should be treated with statins [100], and
recently the use of statins to prevent stroke in Fabry dis-
ease has been discussed [102].
Enzyme replacement therapies (ERTs) are available for
treatment of patients with Fabry disease and several
clinical studies have reported pain outcomes
[45,73,103-112]. For example, the Total Symptom Score
improved with biweekly ERT at the dose of 1 mg/kg for
18 or 23 months [73], and some adults were able to dis-
continue their pain medication(s), or doses of pain med-
ications could be tapered [105,112]. Improvements in
the Bodily Pain scale of the SF-36 during 2 to 3 years of
treatment with ERT (1 mg/kg), particularly in younger
patients, have recently been reported [45]. Signs of
recovery of small nerve fibers have been noted. Signifi-
cant improvements in vibration, heat-pain, and cold per-
ception thresholds, indicating recovery of Ab,A δ-a n d
C-fiber function, have been reported in adults treated
biweekly with 1 mg/kg agalsidase beta for 18 or 23
months [73].
As for the renal [107,113] and cardiac complications
[114] of Fabry disease, early initiation of treatment may
provide a better outcome, i.e., improvement or more
optimal preservation of peripheral nerve function. Addi-
tional studies are needed in pediatric patients to assess
if early-stage treatment can prevent the often devastat-
ing peripheral neurologic burden of Fabry disease.
Conclusions
Small fiber dysfunction accounts for many of the inca-
pacitating complaints reported by most children, adoles-
cents and young adults affected by Fabry disease. These
early complaints (e.g., chronic burning peripheral pain,
attacks of acute excruciating peripheral pain, and mani-
festations of autonomic dysfunction, such as gastroin-
testinal dysmotility and hypohydrosis) should prompt
the clinician to consider the diagnosis Fabry disease and
to perform appropriate tests. The burden of the progres-
sive neurologic disease should be assessed early, com-
prehensively and regularly as the neurologic disability in
Fabry disease increases with age, both in males and
females. Adequate management of the pain is essential
for improving the quality of life of young patients, as are
multidisciplinary management and timely intervention
with disease specific enzyme replacement therapy.
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